Interleukin 1 modulates growth of human renal carcinoma cells in vitro

Koch, Ina; Depenbrock, H.; Danhauser‐Riedl, Susanne; Rastetter, J.; Hanauske, Axel‐R.

doi:10.1038/bjc.1995.154

Cited by 15 publications

(12 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since our aim was to establish a new therapeutic strategy for advanced metastatic clear cell RCC, we selected the Caki-1 cell line, which is derived from skin metastases of clear cell RCC (21), for the in vivo study. To evaluate the enhanced antitumor effect of MKIs by 5FU in vivo, xenograft mice bearing Caki-1 cells were prepared and treated as described in Materials and methods.…”

Section: Combination Effect Of 5fu With Mkis In Caki-1 Xenograft Tumorsmentioning

confidence: 99%

5-fluorouracil enhances the antitumor effect of sorafenib and sunitinib in a xenograft model of human renal cell carcinoma

et al. 2012

View full text Add to dashboard Cite

Section: Combination Effect Of 5fu With Mkis In Caki-1 Xenograft Tumorsmentioning

confidence: 99%

5-fluorouracil enhances the antitumor effect of sorafenib and sunitinib in a xenograft model of human renal cell carcinoma

et al. 2012

View full text Add to dashboard Cite

“…IL-1 modulates the cell growth of the renal cell carcinoma cells in vitro (22). Some GC cell lines express IL-1␣, a cytokine which acts as an autocrine growth stimulator (15).…”

Section: Il-1␤ Expression In Ebvagc In Vivo By Ishmentioning

confidence: 99%

Interleukin-1β Expression in Human Gastric Carcinoma with Epstein-Barr Virus Infection

Chong

Sakuma²,

Sudo

et al. 2002

J Virol

View full text Add to dashboard Cite

The KT tumor is a transplantable strain of a human Epstein-Barr virus (EBV)-associated gastric carcinoma (EBVaGC), established in severe combined immunodeficiency (SCID) mice, with which the cytokine expression of EBVaGC can be investigated without interference from the infiltrating lymphocytes. As a part of a highdensity oligonucleotide array (GeneChip) analysis of EBVaGC, the interleukin-1␤ (IL-1␤) gene was the only cytokine gene that showed markedly higher expression in the KT tumor cells than in two tumor strains of EBV-negative GC. The results were confirmed by Northern blotting, Western blotting, and enzyme-linked immunosorbent assay. Furthermore, we demonstrated a positive signal for IL-1␤ mRNA in the carcinoma cells of a surgically resected EBVaGC, but not in EBV-negative GC, by in situ hybridization. In vitro, IL-1␤ increased the cell growth of a GC cell line, TMK1. Thus, IL-1␤ may act as an autocrine growth factor in EBVaGC.

show abstract

“…Studies have showed the in vitro ability of IL-1 to regulate a variety of cellular functions in tumor cells. [7][8][9] Jin et al reported that IL-1b was expressed in 90% of invasive breast carcinomas and to a lesser extent in ductal in situ carcinomas and benign lesions. 10 Honma et al demonstrated that inflammatory cytokines such as IL-1b regulate proliferation of breast cancer cells through estrogen production by steroid-catalyzing enzymes in the tissue.…”

mentioning

confidence: 99%

Functional variants in the promoter of interleukin‐1β are associated with an increased risk of breast cancer: A case‐control analysis in a Chinese population

Liu

Zhai

Jin

et al. 2006

Intl Journal of Cancer

View full text Add to dashboard Cite

Interleukin 1b (IL-1b) is a multifunctional cytokine that upregulates the inflammatory response, and participates in carcinogenesis, malignant transformation, tumor growth, invasion and metastasis. Two potentially functional polymorphisms (T-31C and C-511T) in the IL-1b gene promoter were suggested to be correlated with alteration of IL-1b expression and therefore may be associated with cancer risk. To test the hypothesis that these 2 polymorphisms are associated with risk of breast cancer, we performed a case-control study of 365 breast cancer cases, 270 patients with benign breast diseases (BBD) and 631 cancer-free controls in a Chinese population. Multivariate logistic regression analyses revealed that increased risk of breast cancer was associated with IL1b-31C variant genotypes [adjusted odds ratio (OR) 5 1.28 and 95% confidence interval (CI) 5 0.91-1.80 for -31CT and 1.72 (95% CI 5 1.16-2.54) for -31CC], compared with the -31TT genotype. Similarly, IL-1b-511T variant genotypes were also associated with increased risk of breast cancer (adjusted OR 5 1.20, 95% CI 5 0.86-1.67 for -511CT and adjusted OR 5 1.74, 95% CI 5 1.18-2.56 for -511TT), compared with the -511CC genotype. Furthermore, cancer risks associated with IL-1bT-31C variant genotypes were more evident in older women, postmenopausal women and individuals with a later menarche age. Interestingly, although we did not find significant associations of these 2 variants with cancer risk when compared with the BBD patients, a 1.27-fold (95% CI 5 1.01-1.60) increased risk was observed with the -31C-511T common haplotype. These findings indicate that these 2 IL-1b promoter variants may contribute to risk of developing breast cancer in the Chinese population. ' 2005 Wiley-Liss, Inc.

show abstract

Interleukin 1 modulates growth of human renal carcinoma cells in vitro

Cited by 15 publications

References 15 publications

5-fluorouracil enhances the antitumor effect of sorafenib and sunitinib in a xenograft model of human renal cell carcinoma

5-fluorouracil enhances the antitumor effect of sorafenib and sunitinib in a xenograft model of human renal cell carcinoma

Interleukin-1β Expression in Human Gastric Carcinoma with Epstein-Barr Virus Infection

Functional variants in the promoter of interleukin‐1β are associated with an increased risk of breast cancer: A case‐control analysis in a Chinese population

Contact Info

Product

Resources

About